September 25, 2018Open Access

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Key Points

Key points are not available for this paper at this time.

Abstract

Durvalumab therapy resulted in significantly longer overall survival than placebo. No new safety signals were identified. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Scott Antonia

Augusto Villegas

Davey B. Daniel

Journals

New England Journal of Medicine

Actions

Institutions

Florida Cancer Specialists & Research Institute

Florida Hospital Cancer Institute

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study